Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016
05/22/2010

Pharmaceutical and healthcare report,” Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market.

Online PR News – 22-May-2010 – – Pharmaceutical and healthcare report,” Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:

Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global allergic conjunctivitis market landscape? - Identify, understand and capitalize.

Companies Mentioned

Novagali Pharma S.A
Fovea Pharmaceuticals SA
Cytos Biotechnology AG
Ono Pharmaceutical Co. Ltd